HEALTH AND MEDICINE

Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype

Leslie Weber1,2,3†, Giacomo Frati4,5, Tristan Felix3,4, Giulia Hardouin3,4, Antonio Casini5, Clara Wollenschlaeger3,4, Vasco Meneghini3,4, Cecile Masson6, Anne De Cian7, Anne Chalumeau1,3,4, Fulvio Mavilio8,9, Mario Amendola10, Isabelle Andre-Schmutz1,4, Anna Cereseto5, Wassim El Nemer11,12,13, Jean-Paul Concordet7, Carine Giovannangeli7, Marina Cavazzana1,4,14, Annarita Miccio3,4†.

Sickle cell disease (SCD) is caused by a single amino acid change in the adult hemoglobin (Hb) β chain that causes Hb polymerization and red blood cell (RBC) sickling. The co-inheritance of mutations causing fetal γ-globin production in adult life hereditary persistence of fetal Hb (HPFH) reduces the clinical severity of SCD. HPFH mutations in the HBG γ-globin promoters disrupt binding sites for the repressors BCL11A and LRF. We used CRISPR-Cas9 to mimic HPFH mutations in the HBG promoters by generating insertions and deletions, leading to disruption of known and putative repressor binding sites. Editing of the LRF-binding site in patient-derived hematopoietic stem/progenitor cells (HSPCs) resulted in γ-globin derepression and correction of the sickling phenotype. Xenotransplantation of HSPCs treated with gRNAs targeting the LRF-binding site showed a high editing efficiency in repopulating HSPCs. This study identifies the LRF-binding site as a potent target for genome-editing treatment of SCD.

INTRODUCTION

β-Hemoglobinopathies (SCD and β-thalassemia) are severe anemias characterized by abnormal or reduced production of hemoglobin (Hb) β chains. SCD and β-thalassemia are the most common monogenic disorders with an incidence of 1 per 318,000 live births worldwide. In β-thalassemia, the reduced production of β chains causes α-globin precipitation and insufficiently hemoglobinized red blood cells (RBCs). In SCD, the β6Glu→Val substitution leads to Hb polymerization and RBC sickling, which is responsible for vaso-occlusive crises, hemolytic anemia, and organ damage.

Allogeneic hematopoietic stem cell (HSC) transplantation is the only definitive cure for patients affected by SCD or β-thalassemia. Transplantation of autologous, genetically modified HSCs represents a promising therapeutic option for patient lacking a compatible HSC donor (1). Pioneering clinical trials based on lentival (LV)–based gene addition approaches demonstrated a clinical benefit in β-thalassemic patients with residual β-globin production (β0-thalassemia). However, this treatment is, at best, partially effective in correcting the clinical phenotype of severe β0-thalassemia (no residual β-globin production) and SCD patients, where higher levels of therapeutic globin are required to restore correct globin chain balance and inhibit HbS polymerization (2–6).

The clinical severity of β-hemoglobinopathies is alleviated by the co-inheritance of genetic mutations causing a sustained fetal γ-globin chain production at adult age, a condition termed hereditary persistence of fetal Hb (HPFH) (7). Elevated fetal γ-globin levels reduce globin chain imbalance in β-thalassemias and exert a potent anti-sickling effect in SCD. Compared with current LV–based gene addition approaches, therapeutic strategies aimed at forcing a β-globin–to–γ-globin switch (8) have the advantage of guaranteeing high-level expression of the endogenous γ-globin genes and, in the case of SCD, reduction of the β5-globin synthesis.

HPFH mutations and single-nucleotide polymorphisms (SNPs) associated with HbF levels of up to 40% of the total Hb were identified at positions −200, −175, −158, and −115 upstream of the HBG1 and HBG2 transcription start sites (TSSs) (Fig. 1A). These mutations either generate de novo DNA motifs recognized by transcriptional activators (9, 10) or disrupt the binding sites for transcriptional repressors. In particular, HPFH mutations in the −200 and −115 regions reduce the binding of LRF and BCL11A transcriptional repressors, respectively, thus inhibiting γ-globin silencing (11, 12). In addition, SNPs at position −158 of both HBG γ-globin promoters are associated with enhanced γ-globin expression (13–17). These SNPs might either identify a putative transcriptional repressor binding site or create a binding site for a transcriptional activator. An ideal and universal strategy to correct the clinical phenotype of patients with β-hemoglobinopathies would be to introduce HPFH mutations in the γ-globin promoters via homology-directed repair (11), which, however, is inefficient in HSCs (18). Here, we mimicked HPFH mutations by disrupting known or putative binding sites for transcriptional repressors in the γ-globin promoters using a CRISPR-Cas9–based genome editing strategy that takes advantage of the nonhomologous
Fig. 1. LRF-binding site disruption induces γ-globin expression in HUDEP-2 cells. (A) Schematic representation of the β-globin locus on chromosome 11, depicting the hypersensitive sites of the locus control region (white boxes) and the HBE1, HBG2, HBG1, HBD, and HBB genes (colored boxes). The sequence of the HBG2 and HBG1 identical promoters (from −210 to −100 nucleotides upstream of the HBG TSS) is shown below. Black arrows indicate HPFH mutations described at HBG1 and/or HBG2 promoters, with the percentage of HbF observed in individuals carrying SCD (*) or β-thalassemia mutations (**). LRF- and BCL11A-binding sites [as described in (11)] are highlighted by orange and green boxes, respectively. The −114/−102 13-bp HPFH deletion is indicated by an empty box. Red arrows indicate the gRNA cleavage sites. (B) Representative RP-HPLC chromatograms are reported together with the expression of γ-like globins (in brackets). The ratio of α chains to non-α chains was similar between HBG-edited and control samples. (E) ChiP-qPCR analysis of H3K27Ac at HBB and HBG promoters in −197-edited HUDEP-2 cells and control AAVal1–edited samples (day 5 of differentiation, n = 3). ChiP was performed using an antibody against H3K27Ac and the corresponding control immunoglobulin G (IgG). ***P ≤ 0.0001, **P ≤ 0.001, *P ≤ 0.01, and P < 0.05 (unpaired t test). SSC, side scatter. (F) ChiP-qPCR analysis of LRF at HBG promoters in −197-edited and control AAVal1–edited K562 cells (n = 2 biologically independent experiments). ChiP was performed using an antibody against LRF. Two different primer pairs were used to amplify the HBG promoters (A and B). KLF1 and DEFB122 served as positive and negative controls, respectively.
end joining (NHEJ)– and microhomology (MH)–mediated end joining (MMEJ)–mediated DNA repair mechanisms to induce insertions and deletions (InDels) within the γ-globin repressor DNA binding motifs. In particular, we show that efficient disruption of known (−200) or putative (−158) binding sites via CRISPR-Cas9 leads to HbF derepression and thus mimics the effect of HPFH mutations and SNPs in erythroid cell lines and in RBCs derived from SCD patients’ hematopoietic stem/progenitor cells (HSPCs). Targeting the LRF-binding site corrects the SCD cell phenotype and is effective in repopulating HSPCs.

RESULTS

Targeting multiple regions in the HBG promoters induces HbF expression in adult HUDEP-2 erythroid cells

We designed guide RNAs (gRNAs) targeting the −200 LRF-binding site (−197, −196, and −195) and the −158 region (−158, −152, and −151) (Fig. 1A). In parallel, we used a gRNA targeting the −115 region (−115) that was reported to induce HbF reactivation by generating a 13–base pair (bp) deletion spanning the BCL11A-binding site (19) and a control gRNA targeting the unrelated AAVS1 locus. Plasmid delivery of individual gRNAs and a Cas9–green fluorescent protein (GFP) fusion in the erythroleukemia cell line KS62 revealed a similar editing efficiency for the gRNAs targeting the −200 region, whereas the −158 gRNA showed the highest editing efficiency at the −158 region. High cleavage efficiency was also observed for the −115 and AAVS1 gRNAs (fig. S1A).

We next used the HUDEP-2 adult erythroid cell line to evaluate γ-globin derepression following disruption of the −200, −158, and −115 regions. After plasmid transfection, bulk populations of Cas9-GFP+ HUDEP-2 cells were differentiated into mature erythroblasts. Overall, genome editing efficiency was ~80% for all the gRNAs tested, with the exception of the −158 gRNA (50 ± 4%; fig. S1B). The editing frequency was similar at days 0 and 9 of erythroid differentiation, thus showing that edited cells were not counterselected during erythroid maturation (fig. S1B). The presence of a −158 C>T heterozygous SNP in the HBG2 promoter resulted in a reduced editing efficiency of HBG2 compared to HBG1 with the gRNA −158 (40 ± 6% versus 68 ± 1%; fig. S1C). Similar editing efficiencies at the HBG1 and HBG2 promoters were observed with the other gRNAs (fig. S1C). Deep sequencing analysis revealed that virtually all the editing events were observed at the −115 and AAVS1 gRNAs (fig. S1A). Efficient editing of the HBG2 promoter resulted in the deletion of the intervening 4.9-kb genomic region and loss of the HBG2 gene, with a frequency ranging from 9 ± 1% to 16 ± 3% (fig. S1E).

Editing of the HBG promoters did not alter erythroid cell differentiation, as assessed by morphological analysis, and flow cytometry and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis of erythroid markers (fig. S2, A to C). Disruption of the −200 region increased the production of γ-globin transcripts and a parallel decrease of adult β-globin and δ-globin mRNA synthesis (Fig. 1B and fig. S2D). Similar changes were observed upon targeting the −115 region, while a lower γ-globin reactivation was observed upon targeting the −158 region (Fig. 1B and fig. S2D). ε-Globin mRNA levels were not significantly different among HBG-edited and control samples (fig. S2D). Flow cytomteric analysis of cells edited at −197, −196, and −195 positions revealed a high frequency of HbF-expressing cells (F cells) (79 ± 1%, 71 ± 1%, and 78 ± 1%). Similar results were obtained by disrupting the −115 region (71 ± 3%), while a lower percentage of F cells (43 ± 5%) was obtained in the −158 edited samples (Fig. 1C). Reversed-phase high-performance liquid chromatography (RP-HPLC) confirmed the significant increase in γ-globin with concomitant decrease of β-globin production following editing of the −200 and the −115 regions, while −158 edited cells displayed a milder increase in γ-globin levels (Fig. 1D). Targeting the LRF-binding site resulted in high HbF levels, accounting for up to 28 ± 1% of the total Hb in −197 samples, as determined by cell-extraction HPLC (CE-HPLC). Cells edited with the −115 gRNA showed comparable HbF reactivation (24 ± 3%), while −158 edited cells showed HbF levels of only 5 ± 2% (fig. S2E). HbF mainly contained δγ (HBG1) rather than δγ (HBG2) chains, which could be explained by loss of HBG2 caused by the 4.9-kb deletion (fig. S2F). Moreover, cells carrying the 4.9-kb deletion may reactivate more potently γ-globin expression, as the HBG1–HBG2 intervening sequence might contain cis regulatory elements that repress HBG transcription. HBG-edited HUDEP-2 showed a normal α chain/non–α chain ratio, indicating that the increased production of γ-globin chains compensated for the reduction of β-globin synthesis (Fig. 1D).

Disruption of the LRF-binding site at both HBG promoters was associated with increased H3K27 acetylation (H3K27Ac), a marker of active regulatory elements (Fig. 1E). Concomitantly, H3K27Ac tended to be reduced at the HBB gene in −197 edited cells compared to control samples (Fig. 1E). As LRF binding cannot be detected at the HBG promoters in wild-type HUDEP-2 cells expressing low HbF levels (11), we evaluated LRF binding in HbF+ K562 edited using the −197 gRNA (66% of editing efficiency) or the AAVS1 control gRNA (72% of editing efficiency). Chromatin immunoprecipitation (ChIP)–qPCR experiments showed a twofold reduction in LRF binding in −200–edited cells.

Efficient editing of the HBG promoters in SCD HSPCs

To test the anti-sickling properties of induced γ-globin synthesis in a clinically relevant model, we edited the γ-globin repressor binding sites in CD34+ HSPCs obtained from SCD patients by plerixafor mobilization (20). We first optimized a selection-free, ribonuclease–protein (RNP)–based protocol (21) to efficiently edit the HBG promoters in CD34+ HSPCs. The use of chemically modified single gRNAs in combination with a transfection enhancer oligonucleotide resulted in the editing of up to 75% of the alleles using the gRNAs targeting the −200 region (fig. S3A). SCD HSPCs were then transected with RNP complexes containing either the gRNAs targeting the HBG promoters or the control AAVS1 gRNA. Following erythroid differentiation, genome editing efficiency in bulk populations of mature erythroblasts achieved values of ≥80% in cells transfected with −197, −196, −195, and −115 gRNAs (Fig. 2A and fig. S3B). Editing frequency with the −158 gRNA was variable because of the presence of the C>T SNP at that position in a fraction of the SCD donors (Fig. 2A and fig. S3B). Genome editing efficiency was similar between the HBG2 and HBG1 promoters, except for samples harboring the −158 SNP and treated with the −158 gRNA (fig. S3B). Of note, the deletion of the 4.9-kb intervening region between HBG2 and HBG1 promoters was not detected in any of the edited primary samples (fig. S3C). This discrepancy between deletion efficiency in HUDEP-2 and HSPCs was also observed in previous studies targeting the −115 region (19, 22) and might be ascribed to a higher expression of the CRISPR-Cas9
Fig. 2. Efficient editing of HBG promoters in HSPCs. (A) Deep sequencing analysis of genome editing events in mature erythroblasts derived from adult SCD and CB healthy donor HSPCs. The InDel profile was unchanged between SCD and healthy donor cells. Frequencies of substitutions (subst), insertions (ins), and deletions (del) are shown as percentages of total InDels. The proportion of >1-bp deletions associated or not with MH motifs is indicated. The frequency of >1-bp deletions associated with MH motifs was significantly lower for the −196 gRNA compared to the −197 (P ≤ 0.01) and −195 (P ≤ 0.001) gRNAs. Data are expressed as means ± SEM (n = 3 to 4, two to three donors). (B) Genome editing efficiency in BFU-E and CFU-GM progenitors derived from edited SCD HSPCs as evaluated by TIDE. Data are expressed as means ± SEM (n = 2 to 5, two SCD donors). (C) Genome editing in single BFU-E and CFU-GM colonies derived from SCD HSPCs as evaluated by TIDE. We plotted the number of edited HBG promoters. In the −158 sample, the donor did not harbor the −158 SNP. (D) InDel profiles generated by each gRNA as analyzed by deep sequencing. The length of MH motifs associated with specific InDels is indicated. Data are expressed as means ± SEM (n = 3 to 4, two to three donors). (E) Genome editing efficiency in subpopulations of −197- and −196-edited CB-derived HSPCs. Cells were FACS-sorted based on the expression of CD34, CD133, and CD90, and genome editing efficiency was determined in committed (CD34+CD133+CD900), early (CD34+CD133−CD900), and primitive (CD34+CD133−CD900) progenitors. We plotted the data of three independent experiments starting from unsorted HSPCs with low, medium, and high genome editing efficiency (three donors).
system in HUDEP-2 cells [transfected with plasmids and FACS (fluorescence-activated cell sorting)—sorted on the basis of Cas9-GFP expression] that favors the simultaneous cleavage of the \( \text{HBG} \) promoters \( (23) \). However, we cannot exclude that transformed cell lines might be more prone to illegitimate repair and can cope easily with large deletions.

Control and edited SCD HSPCs were plated in clonogenic cultures [colony-forming cell (CFC) assay], allowing the growth of erythroid [burst-forming unit–erythroid (BFU-E)] and granulocytic [colony-forming unit–granulomonocytic (CFU-GM)] progenitors. Genome editing efficiency was comparable in pools of BFU-Es and CFU-GMs that showed a similar InDel profile \( (2B \text{ and } S3D) \). Clonal analysis of single CFCs revealed that >85% of hematopoietic progenitors were edited at the target sites, with ~86 and ~67% of BFU-Es and CFU-GMs, respectively, displaying ≥3 edited \( \text{HBG} \) promoters \( (2C) \). Transfection with the full RNP complex reduced the number of hematopoietic progenitors by 10 to 50% compared to transfection of Cas9 protein alone \( (S3E) \).

Previous reports have suggested that HSCs, the target of therapeutic genome editing, are preferentially edited via the NHEJ mechanism \( (24, 25) \). On the contrary, MMEJ repair pathway, which takes place through annealing of short stretches of identical sequence flanking the double-strand break (DSB), may be less active \( (24, 25) \). Therefore, for each gRNA, we evaluated the frequency of mutations with or without MH motifs as a proxy for the relative contribution of MMEJ- and NHEJ-mediated events. In HSPC-derived erythroid bulk populations, among the editing events, deletions were predominant, and a variable fraction of them \( (30 \text{ to } 50\%) \) were associated with the presence of MH motifs in the target sequence \( (2A) \). In particular, MMEJ events at the LRF-binding site can be likely caused by the presence of two stretches of four cytidines \( (1A \text{ and } S1) \). Among the total InDels, the frequency of events associated with MH motifs was significantly higher for the −197 (38 ± 3%) and −195 (32 ± 1%) gRNAs than for the −196 gRNAs (23 ± 1%). The gRNAs targeting the LRF-binding site induced distinct InDel profiles: −196- and −195-edited cells harbored mainly 1-bp insertions and 1- to 2-bp deletions, while the −197 gRNAs generated the largest fraction of 2-bp deletion events, of which ~45% were associated with MH motifs \( (2D \text{ and } S1) \). Virtually all the editing events generated by the −197, −196, and −195 gRNAs disrupted the LRF-binding site \( (S1) \). Of note, the proportion of nucleotides in the LRF-binding site that were lost as a result of editing was higher in −197 than in −196 and −195 samples \( (S4) \). As expected, the −115 gRNA caused disruption of the BCL11A-binding site \( (19) \). In these samples, 13-bp deletions partially spanning the BCL11A-binding site were associated with an 8-bp MH motif and likely mediated by MMEJ \( (S4 \text{ and } S1) \) \( (19) \). Last, the −158 gRNA generated mostly 1-bp insertions and small deletions around the cleavage site \( (2D, \text{fig. } S4, \text{and } S1) \). To evaluate CRISPR-Cas9–mediated genetic modification of the CD34\(^+\) cell fraction containing more primitive HSPCs, \( \text{HBG} \) promoter editing was assessed in FACS-isolated HSPC subpopulations \( (26) \), after transfection of the −197 and −196 gRNAs, associated with high and low frequencies of deletions associated with MH motifs, respectively. Editing frequencies were comparable between primitive CD34\(^+\)/CD133\(^−\)/CD90\(^−\) and early CD34\(^+\)/CD133\(^−\)/CD90\(^−\) progenitors and between CD34\(^+\)/CD133\(^−\) committed progenitors and unsorted CD34\(^+\) cells even in the case of a limited genome editing efficiency, with a similar InDel profile across the different CD34\(^+\) cell subpopulations \( (2E \text{ and } S5) \).

\( \gamma \)-Globin reactivation following LRF-binding site disruption leads to correction of the SCD cell phenotype

To evaluate Hbf reactivation and correction of the SCD cell phenotype upon \( \text{HBG} \) promoter editing, bulk populations of SCD HSPCs were terminally differentiated into enucleated RBCs. Editing of the \( \text{HBG} \) promoters did not affect erythroid differentiation, as evaluated by flow cytometry and RT-qPCR analysis of stage-specific erythroid markers and RBC enucleation and by morphological analysis \( (S6, A \text{ to } C) \). Editing of the −200 region led to increased levels of \( \gamma \)-globin mRNAs, which accounted for 48 ± 3% of total \( \beta \)-like globin transcripts in cells transfected with the −197 gRNA \( (3A) \). \( \epsilon \)-Globin mRNA levels were not significantly different among \( \text{HBG} \)-edited and control samples \( (S6D) \). The proportion of F cells in cells transfected with the −197, −196, and −195 gRNAs was 81 ± 1%, 74 ± 2%, and 74 ± 2%, respectively \( (3B) \). Analysis of −197- and −196-edited erythroblasts sorted by cytofluorimetry based on the intensity of Hbf expression revealed a positive correlation between InDel frequency and extent of \( \gamma \)-globin expression, indicating that the efficacy of Hbf reactivation likely increases when targeting a higher number of \( \text{HBG} \) promoters per cell \( (S6, E \text{ and } F) \). Editing of the −115 region led to \( \text{HBG} \) derepression and a proportion of 80 ± 2% of F cells, while \( \gamma \)-globin reactivation was less pronounced in the −158 samples \( (55 \pm 5\% \text{ of } F \text{ cells; } S3, A \text{ and } B) \). It is noteworthy that for the −158 gRNA, \( \text{HBG} \) derepression was still modest in RBCs derived from HSPCs harboring >85% of edited \( \text{HBG} \) promoters \( (3, A \text{ and } B) \), suggesting that the −158 region contains a sequence that modestly contributes to inhibition of \( \gamma \)-globin expression in adult cells. This is consistent with the mild increase in Hbf known to be associated with the −158 SNPs. However, an alternative hypothesis is that these SNPs generate a DNA motif recognized by a still unknown transcriptional activator; thus, the mechanism of action remains unclear.

RP-HPLC showed a significant increase in \( \gamma \)-globin chain expression and a reciprocal reduction in \( \beta \)-globin levels in the RBC progeny of −200- and −115-edited HSPCs, with no evidence of imbalance in the \( \alpha/\gamma \)-globin chain synthesis \( (3C) \). In −197-edited cells, the increase in \( \gamma \)-globin chains and the reduction of \( \beta \)-globin levels resulted in an inversion of the \( \beta/\gamma \) globin ratio. Comparable \( \lambda^{\gamma}/ \gamma \)- and \( \lambda^{\gamma}/ \gamma \)-globin levels were detected in most of the samples analyzed, consistent with the absence of 4.9-kb deletions. However, in −115-edited cells, Hbf was mainly composed of \( \lambda^{\gamma} \)-globin \( (S6G) \). Unexpectedly, in the −115 samples, the relative frequency of the various editing events was different between \( \text{HBG}1 \) and \( \text{HBG}2 \) promoters, with 13-bp deletions occurring more frequently in \( \text{HBG}2 \) than in \( \text{HBG}1 \), while \( \text{HBG}1 \) editing events were mainly smaller deletions \( (S2) \). This difference in the editing of \( \text{HBG}1 \) and \( \text{HBG}2 \) was unexpected and does not obviously explain the altered \( \lambda^{\gamma}/ \gamma \) ratio in −115-edited samples. CE-HPLC confirmed that editing of the −200 region produced an Hb profile comparable to asymptomatic heterozygous carriers, with Hbf representing up to 47 ± 3% of the total Hb tetramers \( (~197 \text{ samples; } 3D) \). Total Hb levels were comparable between RBCs derived from \( \text{HBG} \)-edited and control HSPCs \( (S6H) \).

To assess the effect of Hbf reactivation on the sickling phenotype, we performed an in vitro deoxygenation assay that induces sickling of RBCs under hypoxia. At an oxygen concentration of 0%, ~80% of control SCD RBCs acquired a sickled shape \( (3, E \text{ and } F) \). Targeting of the −158 region essentially failed to rescue the SCD for.
phenotype (29 ± 13% of nonsickling RBCs; Fig. 3F). In −115-edited samples, HbF reactivation prevented the sickling of 56 ± 9% of RBCs (Fig. 3F). A marked correction of the SCD phenotype was achieved upon disruption of the LRF-binding site, with 69 ± 6% (−196) to 79 ± 7% (−197) of cells that maintained a biconcave shape under hypoxia (Fig. 3F). Even gRNAs generating predominantly 1- to 2-bp InDels (−195 and −196) induced γ-globin levels that were sufficient to inhibit sickling in a large fraction of RBCs. These results
show that editing of the repressor binding sites in the HBG promoters leads to reactivation of HbF sufficient to revert the sickling phenotypes in erythrocytes differentiated from CD34\(^+\) HSPCs derived from SCD patients.

Last, in bulk populations of edited SCD erythroblasts, deep sequencing of top-scoring off-targets identified by GUIDE-seq (27) in 293T cells (fig. S7A) showed low to undetectable off-target activity at most of the sites. An average InDel frequency of ~20% was observed in cells edited with the −196 gRNA within an intergenic site located on chromosome 12 (OT-196.1) (fig. S7B). This site lies ~15-kb away from the nearest gene and does not map to known regulatory elements involved in hematopoiesis.

**Efficient editing of the HBG promoters in repopulating HSPCs**

We next evaluated editing efficiency in repopulating HSPCs. Mobilized healthy donor HSPCs were transfected with −197, −196, −115, or AAVS1 gRNAs. We achieved an average editing efficiency of 77.3 ± 3.7%, 87.4 ± 4.6%, and 89.6 ± 2.8% for the −197, −196, −115 gRNAs, respectively, as measured in in vitro cultured HSPCs, and BFU-E and CFU-GM pools (input cells). Untreated and edited cells were injected into NSG immunodeficient mice, and 16 weeks after transplantation, we analyzed the engraftment of human hematopoietic cells and editing efficiency. The engraftment of control and HBG-edited cells was not statistically different, as analyzed in bone marrow, spleen, and thymus (Fig. 4A), with no skewing toward a particular lineage in any of the samples (fig. S8). Editing efficiency in human cells in the bone marrow and spleen, respectively, was 43.0 ± 9.3% and 33.4 ± 4.0% (−197), 60.3 ± 6.1% and 62.0 ± 1.7% (−196), and 47.6 ± 4.2% and 58.2 ± 3.1% (−115) (Fig. 4B). The −197 gRNA showed a similar InDel profile in the input and in the engrafted human cells, with most of MH motif–associated events occurring at a comparable frequency (Fig. 4C). For the −196 gRNA, events associated to MH motifs were significantly reduced in vivo but were already present at a low frequency in the input populations (Fig. 4C) concordantly with the data obtained in mature erythroblasts in vitro (Fig. 2D). Virtually all editing events disrupt the LRF-binding sites in −197 and −196 samples (Fig. 4C). Last, the frequency of the MH motif–associated 13-bp deletion tended to be lower in the progeny of repopulating HSPCs compared to the input samples, as previously reported (Fig. 4C) (24). Together, these results show that the LRF-binding site can be efficiently targeted in engrafting HSPCs.

**DISCUSSION**

Therapeutic approaches aimed at increasing HbF levels could rely on the down-regulation of nuclear factors involved in γ-globin expression but delays erythroid differentiation (28). Here, we used a CRISPR-Cas9 strategy to disrupt the cis regulatory element involved in LRF-mediated fetal globin silencing and mimic the effect of HPFH mutations. By using three different gRNAs targeting the LRF-binding site, we achieved a robust, virtually pancellular HbF reactivation and a concomitant reduction in β-globin levels, recapitulating the phenotype of asymptomatic SCD-HPPFH patients (29, 30). Notably, a proportion of HbF >30% in 70% of RBCs has been proposed as the minimal requirement to inhibit HbS polymerization and mitigate the clinical SCD manifestations (30). RBCs derived from edited HSPCs displayed HbF levels sufficient to significantly ameliorate the SCD cell phenotype. It is noteworthy that this approach can potentially be applied also to β-thalassemias, where elevated fetal γ-globin levels could compensate for β-globin deficiency.

The development of a selection-free, optimized editing protocol allowed us to obtain a high editing frequency at the LRF-binding site in primary human HSPCs and in HSC-enriched cell populations, which, unexpectedly, showed editing events potentially generated by both NHEJ and MMEJ. However, similarly to the homology-directed repair mechanism (18) [used to correct disease-causing mutations (31–33)], the MMEJ repair pathway occurs in actively dividing cells (34). Therefore, we could not exclude that MMEJ might not be efficient in the quiescent repopulating HSCs (24, 25). Xenotransplantation of HSPCs edited using the gRNAs targeting the LRF- or the BCL11A-binding sites demonstrated a high editing efficiency in repopulating HSPCs and no impairment of their multilineage potential. Similarly to recent studies (24, 35), we observed the persistence in vivo of the 13-bp deletion in the −115 region (although at a lower frequency compared to in vitro cultured HSPCs), which is predicted to be mediated by MMEJ. Upon targeting of the BCL11A enhancer, Wu and colleagues (25) observed a stronger reduction in the frequency of editing events possibly due to MMEJ. In our study, upon targeting of the −200 region, some, but not all, deletions associated with MH motifs and potentially generated via MMEJ were detected at a significantly lower frequency in engrafting HSPCs compared to in vitro cultured HSPCs. Together, these studies suggest that, although at a lower frequency compared to in vitro cultured hematopoietic progenitors, MMEJ can occur in vivo in repopulating HSPCs, in which, however, NHEJ is likely the most active repair pathway. However, as MH motif–associated editing events are “only” computationally predicted to be due to MMEJ, we cannot exclude that a fraction of these events are caused by NHEJ and therefore can occur in repopulating HSPCs.

It is noteworthy that larger deletions typically generated by the −197 edits and associated with an efficient disruption of the LRF-binding sites occur also in vivo. Moreover, even short InDels generated mainly by NHEJ (e.g., −196 gRNA) and detected in repopulating HSPCs are productive in terms of HbF derepression and correction of the SCD cell phenotype. Together, these results show that this strategy can be effective in engrafting HSPCs.

Should the observed editing frequency be confirmed in vivo in patients, this approach would guarantee the efficiency required to achieve clinical benefit in SCD and β-thalassemia. The clinical history of allogeneic HSC transplantation for both diseases suggests that a limited fraction of genetically corrected HSCs would be sufficient to achieve a therapeutic benefit given the in vivo selective survival of corrected RBCs or erythroid precursors (36–41). Disrupting either the LRF- or the BCL11A-binding site in the HBG promoters induced significant HbF production. Given the independent role of LRF and BCL11A in γ-globin repression (28), combined strategies aimed at evicting simultaneously both repressors from the γ-globin promoters could have an additive effect on HbF reactivation. Albeit a Cas9-nuclease–based strategy targeting both LRF and BCL11A repressor binding sites in the γ-globin promoters could have an additive effect on HbF reactivation. Albeit a Cas9-nuclease–based strategy targeting both LRF and BCL11A repressor binding sites in the γ-globin promoters, simultaneously disrupting both LRF and BCL11A repressor binding sites in the γ-globin promoters.

Overall, our study provides proof of concept for a novel approach to treat SCD by targeting a repressor binding site in the γ-globin...
Fig. 4. Editing efficiency in repopulating HSPCs. (A) Engraftment of human cells in NSG mice transplanted with untreated (UT) and edited mobilized healthy donor CD34+ cells (n = 4 mice for each group) 16 weeks after transplantation. Engraftment is represented as percentage of human CD45+ cells in the total murine and human CD45+ cell population, in bone marrow (BM), spleen, thymus, and blood. Values shown are means ± SEM; *P ≤ 0.05 versus untreated [one-way analysis of variance (ANOVA)].

(B) Editing efficiency in the bone marrow– and spleen-derived human CD45+ progeny of repopulating HSPCs, as evaluated by Sanger sequencing and TIDE analysis. The proportion of edited alleles in the input HSPC populations (〇: HSPCs cultured for 6 days in “HSPC medium”; □: BFU-E; △: CFU-GM) is indicated (input). Values shown are means ± SEM. Each data point represents an individual mouse. (C) Genome editing efficiency in the input populations and in bone marrow– and spleen-derived human CD45+ populations edited with the −197, −196, or −115 gRNAs, as evaluated by Sanger sequencing and TIDE analysis. The main events associated with MH-motifs are indicated. Values shown are means ± SEM (n = 4 mice per group). ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus input (unpaired t test).
promoters to induce derepression of fetal Hb and a concomitant decrease in HbS synthesis. The same strategy could be beneficial also in the case of β-thalassemia, potentially providing a more economical gene therapy approach compared to the use of LV vectors to deliver a functional β-globin gene. LV manufacturing is complex and very expensive (44). Our genome editing approach requires the delivery of RNA/protein reagents that might be less expensive than LV production and thus would allow the broader use of gene therapy for β-hemoglobinopathies.

Clinical translation of this genome editing approach requires the development of nontoxic large-scale transfection protocols based on clinical-grade reagents and demonstration of precise editing in a number of HSPCs at least comparable to the efficacious doses predicted by allogeneic transplantation data (i.e., 2 × 10^6 to 3 × 10^6 HSPCs/kg).

**MATERIALS AND METHODS**

**gRNA design and production**

We used CRISPOR (45) to design gRNAs targeting the −200 and −158 regions of the HBG promoters (Table 1). For gRNA expression in erythroid cell lines, oligonucleotide duplexes containing the gRNA protospacers were ligated into Bbs I–digested MA128 plasmid (provided by M. Amendola, Genethon, France). For RNP delivery to HSPCs, we used chemically modified synthetic single gRNAs composed of a tracrRNA (IDT) and a custom crRNA (Synthego) at a concentration of 180 μM. Two-part cr:tracrRNA nonhydrolyzable linkages at the first three 5′ and 3′ nucleotides and 3′-phosphorothioate O-gRNAs harboring 2′-methyl analogs and 3′-phosphorothioate linkages were designed (27) for precise editing and functionality in myeloid and erythroid cells. To deliver the gRNA protospacers into HSPCs, we used chemically modified synthetic single gRNAs harboring 2′-methyl analogs and 3′-phosphorothioate linkages at the first three 5′ and 3′ nucleotides (Synthego) at a concentration of 180 μM. Two-part cr:tracrRNA nonhydrolyzable linkages at the first three 5′ and 3′ nucleotides and 3′-phosphorothioate O-gRNAs harboring 2′-methyl analogs and 3′-phosphorothioate linkages were designed (27) for precise editing and functionality in myeloid and erythroid cells.

**Cell line culture**

K562 were maintained in RPMI 1640 (Lonza) containing glutamine and supplemented with 10% fetal bovine serum (Lonza), Hepes (Life Technologies), sodium pyruvate (Life Technologies), and penicillin and streptomycin (Life Technologies). HUDEP-2 cells (46) were cultured and differentiated, as previously described (47). Flow cytometric analysis of CD36, CD71, and GYPA surface markers and a standard May-Grünwald Giemsa staining were performed to monitor erythroid differentiation.

**HSPC purification and culture**

We obtained human cord blood (CB) CD34+ HSPCs from healthy donors. CB samples eligible for research purposes were obtained because of a convention with the CB bank of Saint Louis Hospital (Paris, France). Human adult SCD CD34+ HSPCs were isolated from Plerixafor mobilized SCD patients (NCT 02212535 clinical trial, Necker Hospital, Paris, France). We obtained granulocyte colony-stimulating factor (G-CSF)–mobilized adult HSPCs from healthy donors. Written informed consent was obtained from all adult subjects. All experiments were performed in accordance with the Declaration of Helsinki. The study was approved by the regional investigational review board (reference: DC 2014-2272, CPP Ile-de-France II “Hôpital Necker-Enfants malades”). HSPCs were purified by immunomagnetic selection with AutoMACS (Miltenyi Biotec) after immunostaining with the CD34 MicroBead Kit (Miltenyi Biotec).Forty-eight hours before transfection, CD34+ cells (10^6 cells/ml) were thawed and cultured in the “HSPC medium” containing StemSpan (STEMCELL Technologies) supplemented with penicillin/streptomycin (Gibco), 250 nM StemRegenin1 (STEMCELL Technologies), and the following recombinant human cytokines (PeproTech): stem cell growth factor, basic fibroblast growth factor, interleukin-3, granulocyte colony-stimulating factor, and granulocyte/macrophage colony-stimulating factor.

**Table 1. gRNA target sequences.**

| gRNA | Target sequence (5′ to 3′) | Position (hg19) | Strand |
|------|---------------------------|----------------|--------|
| AAVS1| GGGGCCAATAAGGCACAGGATGGG | chr19: 55627120–55627139 | – |
| −197 | ATTGAGATAGTGTGGGGAAGGGG | chr11: 5271268–5271287 (HBG1) | + |
| −196 | CATTGAGATAGTGTGGGGAAGGGG | chr11: 5271268–5271287 (HBG1) | + |
| −195 | CATTGAGATAGTGTGGGGAAGGGG | chr11: 5271266–5271285 (HBG1) | + |
| −158 | TATCTGCTGAAACGGTCCCTGG | chr11: 5271243–5271262 (HBG1) | – |
| −152 | CCATGGGTGGAGTTAGCCAGGG | chr11: 5271223–5271242 (HBG1) | + |
| −151 | CCCATGGGTGGAGTTAGCCAGGG | chr11: 5271223–5271242 (HBG1) | + |
| −115 | CTTGTCAGGGCATTGGTCAAGGG | chr11: 5271186–5271205 (HBG1) | + |

Weber et al., Sci. Adv. 2020; 6 : eaay9392  12 February 2020
factor (SCF) (300 ng/ml), Flt-3L (300 ng/ml), thrombopoietin (TPO) (100 ng/ml), and interleukin-3 (IL-3) (60 ng/ml).

**HSPC transfection**

gRNAs were assembled at room temperature with a 90 µM Cas9-GFP protein (provided by De Cian) in RNP complexes using a ratio of 2:1 (gRNA:Cas9). Human CD34+ cells (1 × 10^6 to 2 × 10^6) were transfected with RNP particles using the P3 Primary Cell 4D-Nucleofector X Kit S or L (Lonza), respectively, and the AMAXA 4D CA137 program (Lonza) together with 90 µM transfection enhancer (IDT), unless otherwise stated.

**HSPC differentiation**

Transfected human HSPCs were differentiated into mature RBCs using a three-step protocol (48). From day 0 to day 6, cells were grown in a basal erythroid medium supplemented with the following recombinant human cytokines: SCF (100 ng/ml; PeproTech), IL-3 (5 ng/ml; PeproTech), EPO Eprex (3 IU/ml; Janssen-Cilag), and 10⁻⁶ M hydrocortisone (Sigma). From day 6 to day 9, cells were cultured onto a layer of murine stromal MS-5 cells in a basal erythroid medium supplemented with EPO Eprex (3 IU/ml). Last, from day 9 to day 19, cells were cultured on a layer of MS-5 cells in a basal erythroid medium without cytokines. Erythroid differentiation was monitored by May Grünwald-Giemsa staining; flow cytometric analysis of CD36, CD71, and GYPA erythroid surface markers; and DRAQ5 staining of nucleated cells.

**FACS sorting of HSPC populations**

Healthy donor CB-derived CD34+ HSPCs (10^6) were transfected as described above and plated at a concentration of 500,000/ml in StemSpan (STEMCELL Technologies) supplemented with penicillin/streptomycin (Gibco), 250 nM StemRegenin1 (STEMCELL Technologies), and the following recombinant human cytokines (PeproTech): SCF (300 ng/ml), Flt-3L (300 ng/ml), TPO (100 ng/ml), and IL-3 (60 ng/ml). Eighteen hours after transfection, cells were stained with antibodies recognizing CD34 [CD34 phycoerythrin (PE)–Cy7, 348811; BD Pharmingen], CD133 (CD133 PE, 130-113-748, Miltenyi Biotec), and antibodies recognizing CD34 [CD34 phycoerythrin (PE)–Cy7, 348811; BD Pharmingen], CD133 (CD133 PE, 130-113-748, Miltenyi Biotec), and CD90 (CD90 PE-Cy5, 348811, BD Pharmingen). Cells were sorted using FACSAria II (BD Biosciences). Sorted and unsorted populations were cultured at a concentration of 5 × 10^7/ml in a cytokine-enriched medium (described above) for 4 days before collection for DNA extraction.

**CFC assay**

The number of hematopoietic progenitors was evaluated by clonal CFC assay. HSPCs were plated at a concentration of 1 × 10^3 cells/ml in a methylcellulose-containing medium (GFH4435, STEMCELL Technologies) under conditions supporting erythroid and granulomonocytic differentiation. BFU-E and CFU-GM colonies were scored after 14 days. BFU-Es and CFU-GMs were randomly picked and collected as bulk populations (containing at least 25 colonies) or as individual colonies (35 to 45 colonies per sample) to evaluate genome editing efficiency.

**Detection of genome editing events**

Genome editing was analyzed in HUDEP-2 cells at days 0 and 9 of erythroid differentiation and in CB and adult mobilized HSPC-derived erythroid cells at days 6 and 14 of erythroid differentiation, respectively. Genomic DNA was extracted from control and edited cells using the PureLink Genomic DNA Mini Kit (Life Technologies), Quick-DNA/RNA Miniprep (ZYMEN Research), or DNA Extract All Reagents Kit (Thermo Fisher Scientific) following the manufacturer’s instructions. To evaluate NHEJ efficiency at gRNA target sites, we performed PCR followed by Sanger sequencing and TIDE analysis (tracking of InDels by decomposition) (49) or ICE CRISPR Analysis Tool (Synthego) (Table 2) (50).

Digital droplet PCR was performed using EvaGreen mix (Bio-Rad) to quantify the frequency of the 4.9-kb deletion. Short (~1 min) elongation time allowed the PCR amplification of the genomic region harboring the deletion. Control primers annealing to a genomic region on the same chromosome (chr 11) were used as DNA loading control (Table 3).

**Deep sequencing of on- and off-target sites**

Following PCR amplification of the target sequences with the Phusion High-Fidelity polymerase with GC Buffer (New England BioLabs), amplicons were purified using Ampure XP beads (Beckman Coulter). Illumina-compatible barcoded DNA amplicon libraries were prepared using the TruSeq DNA PCR-Free kit (Illumina). PCR amplification was then performed using 1 ng of double-stranded ligation product and Kapa Taq polymerase reagents (KAPA HiFi HotStart ReadyMix PCR Kit, Kapa Biosystems). After a purification step using Ampure XP beads (Beckman Coulter), libraries were pooled and sequenced using Illumina HiSeq2500 (paired-end sequencing 130 × 130 bases) (Table 4).

For the on-target sites, read pairs were assembled using FLASH. We used a custom python tool suite to count and characterize InDels that were classified in different types: 1-bp deletions, >1-bp deletions non-MH (not associated with MH motifs), >1-bp deletions MH (associated with MH motifs), 1-bp insertions, and >1-bp insertions and substitutions. A tunable window around the cleavage site
(typically of 10 bp) was defined to minimize false-positive InDels, and comparison between treated and control samples was used to call InDels due to treatment versus sequencing errors. For the off-target sites, targeted deep sequencing data were analyzed using CRISPRESSO (51).

**Genome-wide, unbiased identification of DSBs enabled by sequencing**

Human embryonic kidney (HEK) 293T/17 cells (2.5 × 10⁵) were transfected with 500 ng of a SpCas9-expressing plasmid, together with 250 ng of each single-guide RNA–coding plasmid or an empty pUC19 vector (background control), 10 pmol of the bait dsODN (designed according to the original GUIDE-seq protocol), and 50 ng of a pEGFP-IRES-Puro plasmid, expressing both enhanced GFP (EGFP) and the puromycin resistance genes. One day after transfection, cells were replated and selected with puromycin (1 μg/ml) for 48 hours to enrich for transfected cells. Cells were then collected, and genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) and sheared to an average length of 500 bp with the Bioruptor Pico Sonication System (Diagenode). Library preparation was performed using the original adapters and primers according to previous work (27). Libraries were sequenced with a MiSeq sequencing system (Illumina) using an Illumina MiSeq Reagent kit V2-300 cycles (2 × 150-bp paired-end). Raw sequencing data (FASTQ files) were analyzed using the GUIDE-seq computational pipeline (52). Identified sites were considered bona fide off-targets if a maximum of seven mismatches against the on-target were present and if they were absent in the background control. The GUIDE-seq datasets are available in the BioProject repository under the accession number PRJNA531587.

**RT-qPCR analysis of globin and erythroid markers**

Total RNA was extracted from differentiated HUDEP-2 (day 9) and primary mature SCD erythroblasts (day 13) using an RNeasy Micro kit (Qiagen), following the manufacturer’s instructions. Mature transcripts were reverse-transcribed using SuperScript First-Strand Synthesis System for RT-qPCR (Invitrogen) with oligo(dT) primers. RT-qPCR was performed using an iTaq Universal SYBR Green master mix (Bio-Rad) and a Viia7 Real-Time PCR system (Thermo Fisher Scientific) (Table 5).

**RP-HPLC analysis of globin chains**

RP-HPLC analysis was performed using a NexeraX2 SIL-30AC chromatograph and the LC Solution software (Shimadzu). Globin chains were separated by HPLC using a 250 mm × 4.6 mm, 3.6-μm Aeris Widepore column (Phenomenex). Samples were eluted with a gradient mixture of solution A (water/acetonitrile/trifluoroacetic acid, 95:5:0.1) and solution B (water/acetonitrile/trifluoroacetic acid, 5:95:0.1). The absorbance was measured at 220 nm.

---

**Table 4. Primers used for deep sequencing.**

| Amplified region | F/R | Sequence (5′ to 3′) |
|------------------|-----|-------------------|
| HBG promoters    | F   | GGAATGACTGAAATCGGAAACAGG |
|                  | R   | CTGGCCTACTGGAATCTCTT |
| OT−197.1         | F   | GTGGGGTTATAGGAAAGGGCAAGCTG |
|                  | R   | CCTCCACATGACATTTGCC |
| OT−197.2         | F   | CATCTTAAAGAACTGCCAAACAC |
|                  | R   | GATAATGTATGCTGGGTGACCC |
| OT−197.3         | F   | CTTTCAAAAGACGCTAGTGGCTG |
|                  | R   | GGCCGAGTACCTCCCTTCTTATG |
| OT−197.4         | F   | GATAGGACTGCAACTGCCTGGTC |
|                  | R   | CTTCACTGTTTGAACCTAGTTCAT |
| OT−197.5         | F   | CTTCTTCTCTCCCTCTCATAC |
|                  | R   | CTCGTCTGTCCATGCTTCAAAG |
| OT−196.1         | F   | GGTGGGTATAAGAAGGGCAAGCTG |
|                  | R   | CCTCCATCGACATTTGCC |
| OT−196.2         | F   | GCCGGGTTAAGGGCTTGAAGA |
|                  | R   | CCCCCTAACAACACTCTAAAAAC |
| OT−196.3         | F   | ATCACCTAAAACAGAGTCTTCACCTCAGG |
|                  | R   | CGTTCACAACCTGGAAATCTCCTG |
| OT−196.4         | F   | CCCCATTCTTACTAACACGCGGATAC |
|                  | R   | GAGGGGGTTTTAAGGGCAATTTG |
| OT−196.6         | F   | GTATGGCAGCTGACAGGCAACAG |
|                  | R   | GTTGGAGCCCTAAAGGGCAACAG |
| OT−195.1         | F   | ACAAAACATTGTGGGACTTTGGGAAAC |
|                  | R   | CTATGGCCTGATCTCCTCCTGAC |
| OT−195.2         | F   | CATGGCCCACTGGAAGAATAAGCCAAGG |
|                  | R   | CTAATACCTTCTCCTTCACTGGCATAG |
| OT−115.1         | F   | ATGGGGGGGAGACGACCACCATG |
|                  | R   | CATTTTATATACGCTGGCAGGGG |

**Table 5. Primer sequences used for RT-qPCR.**

| Amplified region | F/R | Sequence (5′ to 3′) |
|------------------|-----|-------------------|
| HBA              | F   | CGGTCAACTTCAACGGCCTTAA |
|                  | R   | ACAGAAGCAGGAATTCGTC |
| HBB              | F   | GCAAGGTGAACGTGGATGAAGT |
|                  | R   | TAAAGCAGCTCAGGAGTGACGA |
| HBG1 + HBG2      | F   | CTTGGGAAACCTGCTGCC |
|                  | R   | GGATTGCCAAACACCTGAC |
| HBD              | F   | CAAGGGGACTTCTTCGAG |
|                  | R   | AATTCCTTGCAACAGGATTC |
| HBE              | F   | CTTTGGAACCTGCTGTC |
|                  | R   | CTTGCAAAAGTGAGTAGC |
| GATA1            | F   | GACAGGAGACGCGACCCTACATTAG |
|                  | R   | AGTACTGCGCCGTTTCTAGCAAA |
| ALAS2            | F   | CAGCGCAATGCTGCAAGC |
|                  | R   | TAGATGGCAGCTGGAGAG |
| BAND3            | F   | ACCTCTTCACTCTCCTCCTG |
|                  | R   | AACCTGCTAGCAGTGGTGG |
| GAPDH            | F   | GAAGGTTAGGGCTGGAGAT |
|                  | R   | GAAGATGCTGGATGGATTTC |
CE-HPLC analysis of Hb tetramers

CE-HPLC analysis was performed using a NexeraX2 SIL-30 AC chromatograph and the LC Solution software (Shimadzu). Hb tetramers were separated by HPLC using two cation-exchange columns (PolyCAT A, PolyLC, Columbia, MD). Samples were eluted with a gradient mixture of solution A [20 mM Bis-Tris and 2 mM KCN (pH 6.5)] and solution B [20 mM Bis-Tris, 2 mM KCN, and 250 mM NaCl (pH 6.8)]. The absorbance was measured at 415 nm. The calculation of total Hb levels was performed by integration of the areas under the Hb peaks followed by comparison with a standard Hb control (Lyphochek Hemoglobin A2 Control, Bio-Rad).

Flow cytometric analyses

Differentiated HUDEP-2 cells were fixed and permeabilized using BD Cytofix/Cytoperm solution (BD Pharmingen) and stained with an antibody recognizing HbF [an allophycocyanin (APC)–conjugated anti-HbF antibody, MHF05, Life Technologies or a fluorescein isothiocyanate (FITC)–conjugated anti-HbF antibody, 552829, BD Pharmingen]. HSPC-derived RBCs or erythroblasts were fixed in cold 0.05% glutaraldehyde and permeabilized using 0.1% Triton X-100. After incubation with Fcr Blocking Reagent (Miltenyi Biotec), cells were stained with an FITC-conjugated anti-HbF antibody (552829, BD Pharmingen), as described above. GYPA + cells were labeled with a PE-Cy7–conjugated anti-GYPA antibody (eBioscience) to evaluate the proportion of enucleated RBCs.

ChIP assay

ChIP experiments to detect H3K27Ac were performed as previously described (11) in −197- and AAVS1-edited K562 bulk populations (Table 7).

Sickling assay

HSPC-derived SCD RBCs were exposed to an oxygen-deprived atmosphere (0% O2), and the time course of sickling was monitored in real time by video microscopy, capturing images every 20 min for at least 80 min using an AxioObserver Z1 microscope (Zeiss) and a 40× objective. Images of the same fields were taken throughout all stages and processed with ImageJ to determine the percentage of nonsickled RBCs per field of acquisition in the total RBC population. Cells (~300 to 3300) were counted per condition (1500 cells on average).

NSG mouse transplantation

Nonobese diabetic severe combined immunodeficiency gamma (NSG) mice (NOD.CgPrkdcscid Il2rgtm1Wj/Sjzj, Charles River Laboratories, St Germain sur l’Arbresle, France) were housed in a specific pathogen–free facility. Mice at 6 to 8 weeks of age were conditioned with busulfan (Sigma, St. Louis, MO, USA) injected intraperitoneally (25 mg/kg body weight/day) 24, 48, and 72 hours before transplantation. Control or edited mobilized healthy donor CD34 + cells (106 cells per mouse) were transplanted into NSG mice via retro-orbital sinus injection. Neomycin and acid water were added in the water bottle. At 16 weeks after transplantation, NSG recipients were sacrificed. Cells were harvested from femur bone marrow, thymus, and spleen; stained with antibodies against murine or human surface markers [murine CD45, BD Biosciences, Franklin Lakes, NJ, USA; human CD45, Miltenyi Biotec, Bergisch Gladbach, Germany; human CD3, Miltenyi Biotec, Bergisch Gladbach, Germany; human CD14, BD Biosciences, Franklin Lakes, NJ, USA; human CD15, Beckman Coulter, Brea, CA, USA; human CD19, Sony Biotechnologies, San Jose, CA, USA; human CD235a (CD235a-APC), BD Pharmingen]; and analyzed by flow cytometry using a Gallios analyzer and the Kaluza software (Beckman Coulter, Brea, CA, USA). All experiments and procedures were performed in a facility in which 4°C overnight using an antibody (1 μg per 106 cells) against H3K27Ac (ab4729, Abcam) or a control immunoglobulin G (sc-2025, Santa Cruz Biotechnology). Chromatin cross-linking was reversed at 65°C for at least 4 hours, and DNA was purified using the QIAquick PCR purification kit (Qiagen). We used quantitative SYBR Green PCR (Applied Biosystems) and the Viia7 Real-Time PCR System (Thermo Fisher Scientific) to evaluate H3K27Ac enrichment at different genomic loci (Table 6). ChIP experiments to detect LRF were performed as previously described (11) in −197- and AAVS1-edited K562 bulk populations (Table 7).

| Amplified region | F/R | Sequence (5’ to 3’) |
|------------------|-----|--------------------|
| HBB A            | F   | TCAATGCAATATCTGTCTGAAACG |
|                  | R   | CAAGCCCTTGGTGAAGC |
| HBB B            | F   | CAAATATCTGTCTGAAACGGTCCC |
|                  | R   | CCCAACCCAGGCAAATTG |
| KLF1             | F   | TCGCCTTGGGAGTAGAATG |
|                  | R   | GGCTGCGATGGGCTT |
| DEF8122          | F   | TGGTGCCCTGTTGGGCTT |
|                  | R   | GTGGTCCCTCGGCGAGAAA |

**Table 7. Primers used for ChIP-qPCR (LRF).**
were performed in compliance with the French Ministry of Agriculture’s regulations on animal experiments and were approved by the regional Animal Care and Use Committee (APAFIS#2101-2015090411495178 v4).

**Statistics**

Paired t tests were performed to compare genome editing efficiencies in erythroid subpopulations sorted based on HbF expression. Unpaired t tests were performed for all the other analyses. Statistical analyses were carried out using Prism4 software (GraphPad). We used the Kruskal-Wallis test to compare frequency of deletion generated at each nucleotide by the different gRNAs. The threshold for statistical significance was set to P < 0.05.

**SUPPLEMENTARY MATERIALS**

Supplemental material for this article is available at http://advances.sciencemag.org/cgi/content/full/6/7/eaay9392/DC1

**REFERENCES AND NOTES**

1. M. Cavazzana, C. Antoniani, A. Miccio, Gene therapy for \( \beta \)-hemoglobinopathies. Mol. Ther. 25, 1142–1154 (2017).
2. J. Kanter, J. F. Tisdale, J. L. Kwiatkowski, L. Krishnamurti, M. Y. Mapara, M. Schmidt, Weber Sci. Adv. 6, eaay9392 (2020).
3. View/request a protocol for this paper from HSPC-derived erythroblasts.
4. Table S2. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD.
5. Fig. S8. Cas9/gRNA RNP delivery to HSPCs leads to efficient HBG deletion.
6. Fig. S7. Off-target analysis.
7. Fig. S6. Erythroid maturation and HBG promoters.
8. Fig. S5. Genome editing in stem/progenitor populations.
9. Fig. S4. Deletion frequency at each nucleotide of the HBG promoter.
10. Unpaired in erythroid subpopulations sorted based on HbF expression.

**SUPPLEMENTARY MATERIALS**

Table S58. Deep sequencing analysis of edited HBG promoters in SCD HSPC-derived erythroblasts.

Table S52. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD HSPC-derived erythroblasts.

**View/request a protocol for this paper from Bio-protocol.**

**REFERENCES AND NOTES**

1. M. Cavazzana, C. Antoniani, A. Miccio, Gene therapy for \( \beta \)-hemoglobinopathies. Mol. Ther. 25, 1142–1154 (2017).
2. J. Kanter, J. F. Tisdale, J. L. Kwiatkowski, L. Krishnamurti, M. Y. Mapara, M. Schmidt, Weber Sci. Adv. 6, eaay9392 (2020).
3. View/request a protocol for this paper from HSPC-derived erythroblasts.
4. Table S2. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD.
5. Fig. S8. Cas9/gRNA RNP delivery to HSPCs leads to efficient HBG deletion.
6. Fig. S7. Off-target analysis.
7. Fig. S6. Erythroid maturation and HBG promoters.
8. Fig. S5. Genome editing in stem/progenitor populations.
9. Fig. S4. Deletion frequency at each nucleotide of the HBG promoter.
10. Unpaired in erythroid subpopulations sorted based on HbF expression.

**SUPPLEMENTARY MATERIALS**

Table S58. Deep sequencing analysis of edited HBG promoters in SCD HSPC-derived erythroblasts.

Table S52. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD HSPC-derived erythroblasts.

**View/request a protocol for this paper from Bio-protocol.**

**REFERENCES AND NOTES**

1. M. Cavazzana, C. Antoniani, A. Miccio, Gene therapy for \( \beta \)-hemoglobinopathies. Mol. Ther. 25, 1142–1154 (2017).
2. J. Kanter, J. F. Tisdale, J. L. Kwiatkowski, L. Krishnamurti, M. Y. Mapara, M. Schmidt, Weber Sci. Adv. 6, eaay9392 (2020).
3. View/request a protocol for this paper from HSPC-derived erythroblasts.
4. Table S2. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD.
5. Fig. S8. Cas9/gRNA RNP delivery to HSPCs leads to efficient HBG deletion.
6. Fig. S7. Off-target analysis.
7. Fig. S6. Erythroid maturation and HBG promoters.
8. Fig. S5. Genome editing in stem/progenitor populations.
9. Fig. S4. Deletion frequency at each nucleotide of the HBG promoter.
10. Unpaired in erythroid subpopulations sorted based on HbF expression.

**SUPPLEMENTARY MATERIALS**

Table S58. Deep sequencing analysis of edited HBG promoters in SCD HSPC-derived erythroblasts.

Table S52. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD HSPC-derived erythroblasts.

**View/request a protocol for this paper from Bio-protocol.**

**REFERENCES AND NOTES**

1. M. Cavazzana, C. Antoniani, A. Miccio, Gene therapy for \( \beta \)-hemoglobinopathies. Mol. Ther. 25, 1142–1154 (2017).
2. J. Kanter, J. F. Tisdale, J. L. Kwiatkowski, L. Krishnamurti, M. Y. Mapara, M. Schmidt, Weber Sci. Adv. 6, eaay9392 (2020).
3. View/request a protocol for this paper from HSPC-derived erythroblasts.
4. Table S2. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD.
5. Fig. S8. Cas9/gRNA RNP delivery to HSPCs leads to efficient HBG deletion.
6. Fig. S7. Off-target analysis.
7. Fig. S6. Erythroid maturation and HBG promoters.
8. Fig. S5. Genome editing in stem/progenitor populations.
9. Fig. S4. Deletion frequency at each nucleotide of the HBG promoter.
10. Unpaired in erythroid subpopulations sorted based on HbF expression.

**SUPPLEMENTARY MATERIALS**

Table S58. Deep sequencing analysis of edited HBG promoters in SCD HSPC-derived erythroblasts.

Table S52. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD HSPC-derived erythroblasts.

**View/request a protocol for this paper from Bio-protocol.**

**REFERENCES AND NOTES**

1. M. Cavazzana, C. Antoniani, A. Miccio, Gene therapy for \( \beta \)-hemoglobinopathies. Mol. Ther. 25, 1142–1154 (2017).
2. J. Kanter, J. F. Tisdale, J. L. Kwiatkowski, L. Krishnamurti, M. Y. Mapara, M. Schmidt, Weber Sci. Adv. 6, eaay9392 (2020).
3. View/request a protocol for this paper from HSPC-derived erythroblasts.
4. Table S2. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD.
5. Fig. S8. Cas9/gRNA RNP delivery to HSPCs leads to efficient HBG deletion.
6. Fig. S7. Off-target analysis.
7. Fig. S6. Erythroid maturation and HBG promoters.
8. Fig. S5. Genome editing in stem/progenitor populations.
9. Fig. S4. Deletion frequency at each nucleotide of the HBG promoter.
10. Unpaired in erythroid subpopulations sorted based on HbF expression.

**SUPPLEMENTARY MATERIALS**

Table S58. Deep sequencing analysis of edited HBG promoters in SCD HSPC-derived erythroblasts.

Table S52. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD HSPC-derived erythroblasts.

**View/request a protocol for this paper from Bio-protocol.**

**REFERENCES AND NOTES**

1. M. Cavazzana, C. Antoniani, A. Miccio, Gene therapy for \( \beta \)-hemoglobinopathies. Mol. Ther. 25, 1142–1154 (2017).
2. J. Kanter, J. F. Tisdale, J. L. Kwiatkowski, L. Krishnamurti, M. Y. Mapara, M. Schmidt, Weber Sci. Adv. 6, eaay9392 (2020).
3. View/request a protocol for this paper from HSPC-derived erythroblasts.
4. Table S2. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD.
5. Fig. S8. Cas9/gRNA RNP delivery to HSPCs leads to efficient HBG deletion.
6. Fig. S7. Off-target analysis.
7. Fig. S6. Erythroid maturation and HBG promoters.
8. Fig. S5. Genome editing in stem/progenitor populations.
9. Fig. S4. Deletion frequency at each nucleotide of the HBG promoter.
10. Unpaired in erythroid subpopulations sorted based on HbF expression.

**SUPPLEMENTARY MATERIALS**

Table S58. Deep sequencing analysis of edited HBG promoters in SCD HSPC-derived erythroblasts.

Table S52. Sanger sequencing analysis of −115-edited HBG1 and HBG2 promoters in SCD HSPC-derived erythroblasts.

**View/request a protocol for this paper from Bio-protocol.**
SCIENCE ADVANCES | RESEARCH ARTICLE

28. T. Masuda, X. Wang, M. Maeda, M. C. Canver, F. Shee, A. P. W. Funnell, C. Fisher, M. Suciu, G. E. Martyn, L. J. Norton, C. Zhu, R. Kurita, Y. Nakamura, J. Xu, D. R. Higgs, M. Crossley, D. E. Bauer, S. H. Orkin, P. V. Kharchenko, T. Maeda, Transcriptor factors LRF and BCL11A independently repress expression of fetal hemoglobin. Science 351, 285–289 (2016).

29. I. Akinshaye, A. Alsultani, N. Soloviev, D. Ngo, C. T. Baldwin, P. Sebastiani, D. H. K. Chui, M. H. Steinberg, Fetal hemoglobin in sickle cell anemia. Blood 118, 21–27 (2011).

30. M. H. Steinberg, D. H. Chui, G. J. Dover, P. Sebastiani, A. Alsultani, Fetal hemoglobin in sickle cell anemia: A glass half full? Blood 123, 481–485 (2014).

31. M. A. DeWitt, W. Magis, N. L. Bray, T. Wang, J. R. Berman, F. Urbarini, S. J. Heo, T. Mitos, D. P. Muñoz, D. Boelli, D. B. Kohn, M. C. Walters, D. Carroll, D. I. K. Martin, J. E. Corn, Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. Sci. Transl. Med. 8, 360ra134 (2016).

32. M. D. Hoban, D. Lumaquin, C. Y. Kuo, Z. Romero, J. Long, M. Ho, C. S. Young, M. Mojavidji, S. Fitz-Gibbon, A. R. Cooper, G. R. Lill, F. Urbarini, B. Campo-Fernandez, C. F. Bjurstrom, M. Pellegrini, R. P. Hollis, D. B. Kohn, CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol. Ther. 24, 1561–1569 (2016).

33. D. P. Dever, R. O. Bak, A. Reinsch, J. Camarena, G. Washington, C. E. Nicolas, M. Pavel-Dinu, N. Saxena, A. B. Willkins, S. Mantri, N. Uchida, A. Hendel, A. Narla, R. Majeti, K. I. Weinberg, M. H. Porteus, CRISPR/Cas9-mediated correction of the globin gene targetting in human haematopoietic stem cells. Nature 539, 384–389 (2016).

34. L. N. Truong, Y. Li, L. Z. Shi, P. Y. Hwang, J. He, H. Wang, N. Razavian, M. W. Berns, X. Wu, Microhomology-mediated end resection and homologous recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 110, 7720–7725 (2013).

35. O. Humbert, S. Radtke, C. Samuelson, R. R. Carrillo, A. M. Perez, S. S. Reddy, C. Lux, S. Pattabhi, L. E. Schetter, O. Negre, C. M. Lee, G. Gao, J. E. Adar, C. W. Peterson, D. J. Rawlings, A. M. Scharenberg, H. P. Kiem, Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. Sci. Transl. Med. 11 eaaw3768 (2019).

36. R. S. Franco, Z. Yasin, M. B. Palacsak, P. Circolo, H. C. Joiner, D. L. Rucknagel, The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 108, 1073–1076 (2006).

37. F. Centis, L. Tabellini, G. Lucarelli, O. Buffi, P. Persini, M. Annibali, R. Emiliani, A. C. Komor, A. H. Badran, D. R. Liu, Editing the genome without double-stranded DNA, Nat. Biotechnol. 34, 525–536 (2016).

38. M. Cavazzana, I. Durand-Zaleski, Innovative curative treatment of beta thalassemia: Clinical and conclusions in the paper are present in the paper and/or the Supplementary Materials. Proc. Natl. Acad. Sci. U.S.A. 110, 10547–10552 (2008).

39. P. M. Atkinson, B. Shroff, R. Kerbel, A. M. W. Berns, Genetics of beta thalassemia and C. Bole for the CCAAT box elements and the recruitment of NF-Y. Biochim. Biophys. Acta 964, 23–33 (1988). 1960–1973 (2018).

40. O. Kemeny, L. A. Hugues, J. Christensen, P. J. Tiede, P. J. Tiede, J. C. Hugues, J. M. Dreamer, J. P. Houston, J. D. J. A. Kiem, S. E. Kiefer, C. I. Weinberg, M. H. Porteus, CRISPR/Cas9-mediated correction of the beta thalassemia. Blood 118, 695–697 (2016).

41. E. K. Brinkman, T. Chen, M. Amendola, B. van Steensel, Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).

42. T. Hsaio, D. Comant, N. Rossi, T. Maures, K. Waite, J. Yang, S. Joshi, R. Kelso, K. Holden, B. L. Ensmann, R. Stoner, Inference of CRISPR edits from Sanger trace data. bioRxiv 251082 (Preprint), 10 August 2019. https://doi.org/10.1101/251082.

43. L. Pinello, M. C. Canver, M. D. Hoban, S. H. Orkin, D. B. Kohn, D. E. Bauer, G. C. Yuan, Analyzing CRISPR genome-editing experiments with CRISPRoPress. Nat. Biotechnol. 34, 483 (2016).

44. M. H. Porteus, CRISPR/Cas9-mediated correction of the sickle mutation in human CD34+ cells. Mol. Ther. 24, 665–673 (2016).

45. M. Haeussler, K. Schönig, H. Eckert, A. Eschstruth, J. Mianné, J. B. Renaud, S. H. Orkin, D. B. Kohn, D. E. Bauer, G. C. Yuan, D. E. Bauer, S. H. Orkin, D. B. Kohn, CRISPR/Cas9-mediated editing of the human beta-globin locus. Blood 131, 1960–1973 (2018).

46. M. C. Giarattana, L. Kobari, H. Lapillonne, D. Chalmers, L. Kiger, T. Cynober, M. C. Marden, M. H. Steinberg, J. Roux, J.-P. Concordet, C. Giovannangeli, M. Cavazzana, A. Miccio, Editing a globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci. Adv. 6, eaay9392 (2020).

Acknowledgments: We thank R. Kurita and Y. Nakamura for contributing the HUDEP-2 cell line, L. Douay for the erythroid differentiation protocol, G. Pavani for the optimization of editing protocol in HSPCs, B. Wienert for providing assistance and protocol for the LRF chip, O. Aitblief and C. Bole for the DNA sequencing, E. Brunet for the discussion, and E. Duvernois-Berthet for the script used for InDel characterization. Funding: This work was supported by grants from the European Research Council (ERC-2015-AdG, GENECURE), the Agence Nationale de la Recherche (ANR-16-CE18-0004, ANR-11-INBS-0014-TEFOR, ANR-17-CE13-0016-IIMEJ, and ANR-10-IAHU-01 ‘Investissements d’avenir’ program), the Paris Ile-de-France Region under ‘D Chim Thérapie génique’ initiative, the AFS-Telethon (22339 and 22206), and Genopole (CHAIRE JUNIOR FONDAGEN). Author contributions: L.W. and G.F. designed and conducted the experiments and wrote the paper. T.F., G.H., A.C.A., V.M., and A.C. designed and conducted the experiments. C.M. analyzed off-target NGS data. A.D.C., P.G., A.M. and A.M. designed and conducted the experiments. C.M. analyzed off-target NGS data. A.D.C., P.G., A.M. and A.M. designed and conducted the experiments. C.M. analyzed off-target NGS data. A.D.C. provided reagents. F.M., M.A., J.A.S., A.C., W.E.N., J.P.C., and M.C. contributed to the design of the experimental strategy. A.M. conceived the study, designed the experiments, and wrote the paper.